OS Fund is a venture capital and private equity firm commercializing discoveries in genomics, synthetic biology, artificial intelligence, precision automation, and new materials development that is headquartered in Park Ridge, Illinois and was founded in 2014 by Bryan Johnson, Jeff Klunzinger, and Jeffrey Klunzinger. Notable investments made by OS Fund include: Catalog, Ginkgo Bioworks, Arzeda, Elysium, Emerald Therapeutics, JUST Foods, Synthetic Genomics, Verge Genomics, and Truvian.
OS Fund was founded by Bryan Johnson in 2014, personally funding the venture capital with $100m.
OS Fund I made 28 investments, with 27 receiving follow on investment, four valued at over a billion dollars, and two were acquired. OS Fund invested in entrepreneurs using applied intelligence in genomics, synthetic biology, diagnostics, new materials, and data and energy.
On August 7, 2018 OS Fund announced raising $250 million in capital for their OS Fund II investment fund. At the time of the company's OS Fund II announcement, OS Fund also announced that it has already invested $24.9 million (10% of the capital of OS Fund II) into three technology companies; Arzeda, NuMat Technologies, and UBiome.
Associated Investment Funds
Funding Rounds Participated In
OS Fund -- Building A Global Biological Immune System
OS Fund Raising $250M to Support Entrepreneurs Building Deep Tech to Solve Global Problems